- Home
- BNTX vs LII Comparison
BNTX vs LII Comparison
Compare BNTX & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | LII |
|---|---|---|
| Founded | 2008 | 1895 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 17.7B |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | BNTX | LII |
|---|---|---|
| Price | $92.51 | $497.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 12 |
| Target Price | $137.40 | ★ $603.36 |
| AVG Volume (30 Days) | ★ 1.5M | 509.9K |
| Earning Date | 11-03-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.05% |
| EPS Growth | N/A | ★ 12.46 |
| EPS | N/A | ★ 23.67 |
| Revenue | $3,698,814,972.00 | ★ $5,345,300,000.00 |
| Revenue This Year | $2.36 | N/A |
| Revenue Next Year | N/A | $7.34 |
| P/E Ratio | ★ N/A | $21.00 |
| Revenue Growth | 3.70 | ★ 3.77 |
| 52 Week Low | $81.20 | $443.19 |
| 52 Week High | $129.27 | $689.44 |
Technical Indicators
Market Signals| Indicator | BNTX | LII |
|---|---|---|
| Relative Strength Index (RSI) | 35.58 | 51.76 |
| Support Level | $91.11 | $486.48 |
| Resistance Level | $93.76 | $508.94 |
| Average True Range (ATR) | 2.08 | 13.39 |
| MACD | -0.33 | 0.14 |
| Stochastic Oscillator | 15.27 | 38.32 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.